Zealand Pharma Announces Completion of Enrollment in Phase 2b ZUPREME-1 Trial of Petrelintide
Zealand Pharma A/S, a biotech company specializing in the development of peptide-based medicines, recently announced the successful completion of enrollment in the Phase 2b ZUPREME-1 trial for petrelintide. This trial is designed to assess the safety, tolerability, and efficacy of petrelintide in individuals with overweight or obesity.
About Petrelintide
Petrelintide is a once-weekly injectable GLP-1 receptor agonist that has been developed to help manage weight in people with overweight or obesity. It is designed to mimic the natural hormone GLP-1, which plays a crucial role in regulating appetite and satiety.
Design of the ZUPREME-1 Trial
Initiated in December 2024, the randomized, double-blind, placebo-controlled Phase 2b ZUPREME-1 trial is being conducted at approximately 100 sites in 11 countries. The study aims to evaluate five target doses of petrelintide, ranging from 1 mg to 9 mg, over a 42-week treatment period.
Impact on Individuals
For people struggling with overweight or obesity, the completion of this trial signifies a potential new treatment option on the horizon. Petrelintide’s ability to mimic GLP-1 could help manage appetite, improve satiety, and ultimately assist in weight loss. Successful results from this trial could pave the way for further studies and eventual approval for use in clinical practice.
Impact on the World
Obesity is a growing global health concern, and the completion of the ZUPREME-1 trial could lead to a significant advancement in the treatment of this condition. According to the World Health Organization, approximately 1.9 billion adults were overweight or obese in 2016, and this number is projected to increase to 2.7 billion by 2025. Effective treatments for obesity could help reduce the burden on healthcare systems and improve overall population health.
Conclusion
The successful completion of the Phase 2b ZUPREME-1 trial marks an important step forward in the development of petrelintide as a potential treatment for overweight and obesity. With the potential to mimic the natural hormone GLP-1, petrelintide could offer a new approach to managing appetite and promoting weight loss. Successful results from this trial could lead to further studies and, ultimately, approval for use in clinical practice. The potential impact on individuals struggling with overweight or obesity, as well as on the global healthcare landscape, is significant.
- Zealand Pharma completes enrollment in Phase 2b ZUPREME-1 trial for petrelintide
- Petrelintide is a once-weekly injectable GLP-1 receptor agonist designed to manage weight in people with overweight or obesity
- Trial aims to evaluate five target doses of petrelintide over a 42-week treatment period
- Successful results could pave the way for further studies and eventual approval for use in clinical practice
- Obesity is a growing global health concern, and effective treatments could help reduce the burden on healthcare systems and improve population health
